Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking

05-Feb-2020 - Domain Therapeutics announced that it has been granted a patent in the US and in Europecovering a novel family of biosensors. The patent, entitled ‘Biosensors for monitoring biomolecule localization and trafficking in cells’, was initially filed by Prof. Michel Bouvier and his team and is part ...

Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop mGluR4 PAMs for Parkinson’s disease

29-Jan-2013 - Domain Therapeutics S.A. announced that Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease. This agreement between Domain Therapeutics and ...

Domain Therapeutics enters into collaboration agreement with Ono in the field of GPCR-based drug discovery

23-Oct-2012 - Domain Therapeutics S.A. announced that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).Under the agreement, Ono will provide Domain Therapeutics with an ...

Domain Therapeutics wins EUR 933,000 grant for schizophrenia project

GPCR specialist will lead EUR 5.1 million ATHOS Project to develop new therapies

16-Mar-2012 - Domain Therapeutics announced that the ATHOS project has been selected for French government funding. ATHOS aims to develop new drug candidates and identify therapeutic targets for schizophrenia.Total funding will amount to EUR 5.1 million over three years. Some 45 per cent of the ATHOS budget ...